[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Table 4

Distribution of patients with HBeAg <0.5PEIU/mL and anti-HBe (+) at different time periods.

Indicators (months)	Control group (n = 26)	Tenofovir group (n = 26)	Entecavir group (n = 26)
3	5 (19.23%)	13 (50.00%)#&	10 (38.46%)#
6	8 (30.77%)^∗	17 (65.38%)^∗#&	14 (53.85%)^∗#
12	10 (38.46%)^∗@	21 (80.77%)^∗@#&	18 (69.23%)^∗@#